Diabetes-induced oxidative stress and chronic inflammation in the retina play a key pathogenic role in diabetic retinopathy (DR). Mitochondrial dysfunction and impairment have been identified as the major cause of oxidative stress and inflammation in DR. Peroxisome Proliferator-Activated Receptor ? (PPAR?) is a hormone- activated receptor and transcription factor. It is known to regulate lipid metabolism, and thus, PPAR? agonists are used clinically to treat hyperlipidemia. Recently, two independent, prospective clinical studies reported a surprising finding that oral administration of fenofibrate, a PPAR? agonist, has robust therapeutic effects on DR in type 2 diabetic patients. In the prior grant period, we have successfully demonstrated that the therapeutic effect of fenofibrate on DR is through a PPAR?-dependent mechanism. We have shown that PPAR? is down- regulated in the retinas of diabetic humans and diabetic animal models, and PPAR? has protective effects against DR. We have shown that PPAR? knockout (KO) exacerbated, while activation of PPAR? by fenofibrate alleviated retinal oxidative stress and retinal inflammation in DR models. This proposal will extend these studies and elucidate the mechanism responsible for the protective effects of PPAR?. Our preliminary studies showed that fenofibrate treatment decreased diabetes-induced acellular capillary formation and pericyte loss in the retina. Further, Seahorse analysis showed that PPAR? KO resulted in mitochondrial dysfunction in the retina and primary pericytes. Further, PPAR?-/- retina showed decreased mitochondrial DNA (mtDNA) copy numbers, suggesting impaired mitochondrial biogenesis and/or DNA repair. This project will address a novel hypothesis that diabetes-induced down-regulation of PPAR? expression is responsible for, at least in part, for diabetes-induced mitochondrial dysfunction, which leads to retinal oxidative stress and inflammation in DR. We will determine if PPAR? KO exacerbates, while PPAR? over-expression alleviates, mitochondrial dysfunction (basal OCR, maximal OCR and ATP production) and mtDNA damage as well as retinal oxidative stress, leukostasis, vascular leakage, acellular capillary formation and pericyte dropout in the retina of diabetic mice. We will also determine the impacts of PPAR? deficiency in pericytes on diabetes-induced mitochondrial damage, oxidative stress and pericyte apoptosis using pericyte-specific conditional PPAR? KO mice and primary PPAR?-/- pericytes. We will also investigate if PPAR? regulates mitochondrial biogenesis and function through the SIRT1/PGC-1? pathway using pericyte-specific SIRT1 KO mice and primary SIRT1-/- pericytes. These studies will elucidate a novel pathogenic mechanism responsible for mitochondrial damage and oxidative stress in DR and reveal a new therapeutic strategy for DR. These studies will also contribute to the understanding of the mechanism underlying therapeutic effects of fenofibrate on retinal inflammation and pericyte loss in DR.

Public Health Relevance

Diabetic retinopathy is a common complication of diabetes and the leading cause of blindness in the working age population. Fenofibrate is the first oral drug ever with proven effects on diabetic retinopathy in type 2 diabetic patients by two independent clinical studies. This project will elucidate the mechanism responsible for the therapeutic effect of fenofibrate on diabetic retinopathy. The proposed studies will explore a novel pathogenic mechanism, i.e. the diabetes-induced down-regulation of PPAR? is responsible for retinal oxidative stress and inflammation in diabetic retinopathy. These studies are of clinical relevance and will contribute to the development of new drug treatment for diabetic retinopathy.

National Institute of Health (NIH)
National Eye Institute (NEI)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Shen, Grace L
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Oklahoma Health Sciences Center
Schools of Medicine
Oklahoma City
United States
Zip Code
Wang, Bing; Li, Pui-Kai; Ma, Jian-Xing et al. (2018) Therapeutic Effects of a Novel Phenylphthalimide Analog for Corneal Neovascularization and Retinal Vascular Leakage. Invest Ophthalmol Vis Sci 59:3630-3642
Shin, Younghwa; Moiseyev, Gennadiy; Petrukhin, Konstantin et al. (2018) A novel RPE65 inhibitor CU239 suppresses visual cycle and prevents retinal degeneration. Biochim Biophys Acta Mol Basis Dis 1864:2420-2429
Chen, Qian; Qiu, Fangfang; Zhou, Kelu et al. (2017) Pathogenic Role of microRNA-21 in Diabetic Retinopathy Through Downregulation of PPAR?. Diabetes 66:1671-1682
Malechka, Volha V; Moiseyev, Gennadiy; Takahashi, Yusuke et al. (2017) Impaired Rhodopsin Generation in the Rat Model of Diabetic Retinopathy. Am J Pathol 187:2222-2231
Qiu, Fangfang; Liu, Zhen; Zhou, Yueping et al. (2017) Decreased Circulating Levels of Dickkopf-1 in Patients with Exudative Age-related Macular Degeneration. Sci Rep 7:1263
Pearsall, Elizabeth A; Cheng, Rui; Zhou, Kelu et al. (2017) PPAR? is essential for retinal lipid metabolism and neuronal survival. BMC Biol 15:113
Qiu, Fangfang; Matlock, Greg; Chen, Qian et al. (2017) Therapeutic Effects of PPAR? Agonist on Ocular Neovascularization in Models Recapitulating Neovascular Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci 58:5065-5075
He, Xuemin; Cheng, Rui; Park, Kyoungmin et al. (2017) Pigment epithelium-derived factor, a noninhibitory serine protease inhibitor, is renoprotective by inhibiting the Wnt pathway. Kidney Int 91:642-657
Deng, Guotao; Moran, Elizabeth P; Cheng, Rui et al. (2017) Therapeutic Effects of a Novel Agonist of Peroxisome Proliferator-Activated Receptor Alpha for the Treatment of Diabetic Retinopathy. Invest Ophthalmol Vis Sci 58:5030-5042
Shin, Younghwa; Moiseyev, Gennadiy; Chakraborty, Dibyendu et al. (2017) A Dominant Mutation in Rpe65, D477G, Delays Dark Adaptation and Disturbs the Visual Cycle in the Mutant Knock-In Mice. Am J Pathol 187:517-527

Showing the most recent 10 out of 61 publications